---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic impact of diagnostic testing"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic impact of diagnostic testing. Topics: Medicare payment for liquid biopsy and tissue genomic sequencing panels, Clinical Laboratory Fee Schedule fourth-quarter file; Advanced Diagnostic Laboratory Test status and initial-period payment for Guardant360 CDx and FoundationOne Liquid CDx; Medicare national coverage of next-generation sequencing companion diagnostics in advanced cancer; State biomarker testing insurance coverage laws; 4 further topics. 8 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/economic-impact-of-diagnostic-testing"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic impact of diagnostic testing

<a id="heading-2.2.1.8.4"></a>

## 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

### Medicare payment for liquid biopsy and tissue genomic sequencing panels, Clinical Laboratory Fee Schedule fourth-quarter file

| Code | Short description in the file | Rate in the file (U.S. dollars) |
| --- | --- | --- |
| 0242U | “Trgt gen seq alys pnl 55-74” | “05000.00” |
| 0239U | “Trgt gen seq alys pnl 311+” | “03500.00” |
| 0326U | “Trgt gen seq alys pnl 83+” | “05000.00” |
| 81455 | “So/hl 51/>gsap dna/dna&rna” | “02919.60” |

Source: [CMS Clinical Laboratory Fee Schedule file 26CLABQ4 (2026)](https://www.cms.gov/files/zip/26clabq4.zip)

> “Note: Including a code or payment amount for a particular clinical diagnostic laboratory test doesn't imply Medicare will cover the test.”
> “CY 2026 Q4 Release: Updated for October 2026.”

Source: [CMS Clinical Laboratory Fee Schedule (2026)](https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule-clfs/files)

<a id="topic-2.2.1.8.4-2"></a>

### Advanced Diagnostic Laboratory Test status and initial-period payment for Guardant360 CDx and FoundationOne Liquid CDx

| Test code | Laboratory | Test name | Payment amount during new ADLT initial period |
| --- | --- | --- | --- |
| 0242U | “Guardant Health, Inc.” | “Guardant360 CDx” | “$5,000.00” |
| 0239U | “Foundation Medicine, Inc.” | “FoundationOne Liquid CDx” | “$3,500.00” |

Source: [CMS ADLT list (2026)](https://cms.gov/files/document/advanced-diagnostic-laboratory-tests-under-medicare-clfs.pdf)

<a id="topic-2.2.1.8.4-3"></a>

### Medicare national coverage of next-generation sequencing companion diagnostics in advanced cancer

> “Effective for services performed on or after March 16, 2018, the Centers for Medicare & Medicaid Services (CMS) has determined that Next Generation Sequencing (NGS) as a diagnostic laboratory test is reasonable and necessary and covered nationally, when performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, when ordered by a treating physician, and when all of the following requirements are met:”
> “Patient has: either recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer; and not been previously tested with the same test using NGS for the same cancer genetic content, and decided to seek further cancer treatment (e.g., therapeutic chemotherapy).”
> “The diagnostic laboratory test using NGS must have: Food & Drug Administration (FDA) approval or clearance as a companion in vitro diagnostic; and, an FDA-approved or -cleared indication for use in that patient’s cancer; and, results provided to the treating physician for management of the patient using a report template to specify treatment options.”

Source: [CMS National Coverage Determination 90.2 (2020)](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=372)

<a id="topic-2.2.1.8.4-4"></a>

### State biomarker testing insurance coverage laws

> “Cost and lack of insurance coverage are common barriers to testing because insurance coverage varies across commercial payers, Medicare, and Medicaid.”
> “Fifteen states have passed legislation related to biomarker testing since 2021”
> “All laws apply to commercial payers; in 12 states, the laws also apply to Medicaid.”
> “Most laws (n = 11) require coverage of biomarker testing broadly without regard to condition. Four states (Arkansas, California, Louisiana, and Nevada) specify coverage of cancer biomarkers, with California specifying coverage for testing for stage III or IV cancer only.”

Source: [Lin et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11590753/)

<a id="topic-2.2.1.8.4-5"></a>

### Managed care perspectives on ESR1 and circulating tumor DNA testing costs and coverage

> “Key insight: A primary consideration of payers in aBC is that the optimal biomarker testing parameters are uncertain, which leads to inconsistent testing practices and the need for management that promotes consistency while mitigating delays in care such as via treatment pathways.”
> “Participants also recognized that although the cost of additional biomarker testing may not be realized by the provider or patient, it could be a cost-of-care consideration for payers including employer groups.”
> “Payer participants expressed concern with regular, potentially costly testing if it does not result in actionable information for making treatment decisions.”

Source: [Flavin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13622885/)

<a id="topic-2.2.1.8.4-6"></a>

### Coverage and out-of-pocket cost barriers to next-generation sequencing reported by US stakeholders in metastatic breast cancer

> “This study revealed that despite the awareness and recognition of the value proposition of NGS-based molecular profiling in mBC, inconsistent payer coverage, high out of pocket costs for patients, and challenges in managing reimbursement and prior authorization processes can lead to suboptimal utilization of NGS, which can subsequently lead to suboptimal treatment decisions where approved therapies exist.”
> “Interestingly, many payers (33%) were not aware of the current somatic biomarker testing recommendations from NCCN guidelines.”

Source: [Cadirov et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12564138/)

<a id="topic-2.2.1.8.4-7"></a>

### ESR1 testing rates by line of therapy in US practice

> “Testing rates at 1L initiation were 36.2% in endocrine-resistant MBC and 19.6% in endocrine-sensitive/de novo MBC. Testing rates were approximately 32% at second line and 25% at third line across subgroups.”

Source: [Liao et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13710441/)

<a id="topic-2.2.1.8.4-8"></a>

### Specimen type and turnaround time of ESR1 tests during first-line therapy in US practice

> “Among 7772 patients with mBC in the FHRD who initiated 1 L therapy, tumor ESR1 mutation status was evaluated for 222 (3%) patients at baseline (≤ 90 days before 1 L) and 1355 (17%) during 1 L.”
> “Most (60%) tests during 1 L used tissue specimens, while the remaining 40% were liquid biopsies, and the median time from specimen collection to result reporting in 1 L was 28 (IQR:10–84) days.”

Source: [Meisel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13558280/)

Additional sources: [Bello et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42002527/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
